Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Parkinson’s Disease – Unmet Need – Unmet Need – Levodopa-Induced Dyskinesia (US/EU)
Levodopa-induced dyskinesia (LID) is a complication stemming from the long-term use of levodopa to treat Parkinson’s disease (PD); it causes abnormal involuntary movements. Surveyed neurologists…
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…
Parkinson’s Disease – Current Treatment – Current Treatment: Physician Insights -Parkinson’s Disease (US)
The treatment of Parkinson’s disease (PD) requires personalized care, a high degree of polypharmacy, and frequent adjustments to achieve symptom control throughout the disease course…
Parkinson’s Disease – Geographic Focus: China – Parkinson’s Disease – China In-Depth (China)
Parkinson’s disease is a chronic neurodegenerative disease characterized by progressively worsening motor symptoms. Treatment of Parkinson’s disease in China comprises a broad range of…
Parkinson’s Disease – Emerging Therapies – Special Topics: Novel Entrants in the Parkinson’s Disease Market (US)
Core to Parkinson’s disease (PD) treatment is the co-prescription of various formulations of the gold-standard SOC levodopa with a range of adjunctive therapies from other drug classes (e.g.,…
Parkinson’s Disease – Access & Reimbursement – Access & Reimbursement – Parkinson’s Disease (US)
Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…
